Gaisbock syndrome

Summary

Gaisbock syndrome (MONDO:0019538) is a disease. A subtype of acquired secondary polycythemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Phenotypes (HPO): 36

Clinical features

Signs & symptoms

Clinical features (HPO)

36 HPO clinical features (Orphanet curated; top 36 by frequency):

HPO ID	Term	Frequency
HP:0000822	Hypertension	Very frequent (80-99%)
HP:0001050	Plethora	Very frequent (80-99%)
HP:0001899	Increased hematocrit	Very frequent (80-99%)
HP:0011106	Hypovolemia	Very frequent (80-99%)
HP:0020059	Increased red blood cell count	Very frequent (80-99%)
HP:0025548	Increased mean corpuscular hemoglobin concentration	Very frequent (80-99%)
HP:0025619	Elevated plasma cell count	Very frequent (80-99%)
HP:0100724	Hypercoagulability	Very frequent (80-99%)
HP:0000739	Anxiety	Frequent (30-79%)
HP:0000848	Increased circulating renin level	Frequent (30-79%)
HP:0001513	Obesity	Frequent (30-79%)
HP:0002149	Hyperuricemia	Frequent (30-79%)
HP:0002152	Hyperproteinemia	Frequent (30-79%)
HP:0002155	Hypertriglyceridemia	Frequent (30-79%)
HP:0002315	Headache	Frequent (30-79%)
HP:0002321	Vertigo	Frequent (30-79%)
HP:0003124	Hypercholesterolemia	Frequent (30-79%)
HP:0003394	Muscle spasm	Frequent (30-79%)
HP:0004950	Peripheral arterial stenosis	Frequent (30-79%)
HP:0005117	Elevated diastolic blood pressure	Frequent (30-79%)
HP:0012378	Fatigue	Frequent (30-79%)
HP:0012605	Hypernatriuria	Frequent (30-79%)
HP:0025502	Overweight	Frequent (30-79%)
HP:0001082	Cholecystitis	Occasional (5-29%)
HP:0001297	Stroke	Occasional (5-29%)
HP:0001658	Myocardial infarction	Occasional (5-29%)
HP:0001677	Coronaryartery atherosclerosis	Occasional (5-29%)
HP:0001681	Angina pectoris	Occasional (5-29%)
HP:0002094	Dyspnea	Occasional (5-29%)
HP:0004398	Peptic ulcer	Occasional (5-29%)
HP:0100785	Insomnia	Occasional (5-29%)
HP:0410019	Epigastric pain	Occasional (5-29%)
HP:0001744	Splenomegaly	Excluded (0%)
HP:0000121	Nephrocalcinosis	Very rare (<1-4%)
HP:0000819	Diabetes mellitus	Very rare (<1-4%)
HP:0001997	Gout	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	Gaisbock syndrome
Mondo ID	MONDO:0019538
Orphanet	90041
DOID	DOID:2838
ICD-11	533704171
NCIT	C27174
SNOMED CT	36874002
UMLS	C2242785
MedGen	745735
GARD	0019104
MedDRA	10042217, 10053885
Is cancer (heuristic)	no

Also known as: Gaisboeck’s syndrome · Pseudopolycythaemia · Pseudopolycythemia · stress erythrocytosis · stress polycythemia

Disease family

This is a subtype of acquired secondary polycythemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › bone marrow disorder › polycythemia › acquired polycythemia › acquired secondary polycythemia › Gaisbock syndrome

Related subtypes (3): dehydration polycythemia, erythropoietin polycythemia, polycythemia due to hypoxia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.